Pq Bypass

PQ Bypass Announces $60M Financing

PQ Bypass Announces $60 Million Financing to Advance New Therapeutic Approach to Peripheral Arterial Disease. Funds Will Support Pivotal Trial of Novel DETOUR System Designed for Patients with Tough to Treat Long Blockages in Leg Arteries.

January 08, 2019. Ireland and California, USA. Seroba’s portfolio company, PQ Bypass, Inc., a medical device company dedicated to advancing treatment options for patients with peripheral arterial disease (PAD), has entered into an agreement that provides for up to an aggregate of $60 million in equity financing, led by Deerfield Management.

Joining the round are existing investors, including Seroba Life Sciences and MedTech Venture Partners. The financing round also allowed the company to convert approximately $15 million in outstanding convertible debt and interest to equity. Funds will be used to advance the clinical development of the company’s technology for the treatment of long blockages in leg arteries caused by PAD.

“We are very fortunate to have Deerfield as an anchor investor and, together, we are working to develop a minimally-invasive treatment alternative for a disease that affects millions of people, worldwide. With this funding we continue our pursuit of the science that will bring us closer to commercial release of this important advancement in the care of patients with PAD,” said Richard Ferrari, Chairman and Chief Executive Officer of PQ Bypass. “We are very fortunate to have Deerfield as an anchor investor and, together, we are working to develop a minimally-invasive treatment alternative for a disease that affects millions of people, worldwide.”

In people with PAD, leg arteries can become blocked by long segments of plaque that restrict blood flow to the lower leg and foot. This can lead to pain, loss of mobility and even amputation. Extremely long blockages, such as those greater than 20 centimeters, are quite challenging to treat. Historically, physicians have performed open bypass surgery, which has the benefit of durability; however, it is associated with an increased risk of complications, lengthy hospital stays and prolonged rehabilitation. Minimally invasive approaches, including angioplasty and stenting, work very well on shorter blockages; however, they have not been as effective on longer ones, often resulting in repeat procedures within one year.

Percutaneous femoropopliteal bypass (the DETOUR procedure) is designed to provide the durability of open bypass with the benefits of a minimally-invasive approach. In this procedure, PQ Bypass’ proprietary stent graft technology is placed from the superficial femoral artery, into the femoral vein, and back into the popliteal artery to create a detour around the blockage. The stent graft bypass re-directs oxygen-rich blood, with the goal of restoring blood flow to the lower leg and foot of the patient.

“PQ Bypass has developed a novel technology and procedure to address a true clinical conundrum in the treatment of long lesions from PAD. This technology has the potential to be the standard of care for the segment of PAD patients who, today, have to choose between either an open surgical treatment that lasts longer or less-invasive treatment options that potentially fail approximately 50% of the time. In addition to improving outcomes for patients, this has the potential to significantly reduce the cost burden of long lesion PAD,” said Andrew ElBardissi, M.D., of Deerfield.

About Peripheral Artery Disease (PAD)

Peripheral Artery Disease, or PAD, is a common but serious circulatory condition wherein adequate blood flow does not reach the limbs due to a build-up of fatty deposits and calcium on the artery walls. If severe enough, blocked blood flow can cause tissue death and can sometimes lead to amputation of the foot or leg.
Lower extremity PAD is the third leading cause of atherosclerotic cardiovascular morbidity, following coronary artery disease and stroke. Systematic reviews indicate that PAD affects over 200 million people worldwide—and the prevalence of PAD is increasing as “baby boomers” enter high-risk age groups. With estimates of more than 20% of the population projected to age into the 65-and-over cohort by the year 2050, PAD is a growing epidemic with staggering social and economic costs.

About the DETOUR II Trial

The DETOUR II trial is the first and only pivotal investigational trial in the United States for percutaneous bypass. Currently underway, the trial will enroll up to 292 patients at up to 40 sites across the United States and Europe, and is led by national co-Principal Investigators Sean Lyden, MD, FACS and Chairman of the Department of Vascular Surgery at the Cleveland Clinic, and Jihad Mustapha, MD, FACC, FSCAI, CEO at Advanced Cardiac and Vascular Amputation Prevention Centers. The DETOUR II trial aims to expand the body of evidence evaluating the safety and effectiveness of the DETOUR System to create a percutaneous femoropopliteal bypass. More details can be found at clinicaltrials.gov, trial identifier NCT03119233.

About PQ Bypass

PQ Bypass is operated by recognized leaders in the medical device industry including veterans from Medtronic, Abbott, Johnson & Johnson, and Stryker. The underlying technology and technique used in the DETOUR percutaneous femoropopliteal bypass procedure were co-developed by two world-renowned cardiologists and innovators, Dr. James Joye and Dr. Richard Heuser, who are recognized experts in peripheral artery disease.

In March 2017, PQ Bypass received CE (Conformité Européenne) Mark approval for the DETOUR™ System.

In August 2017, Frost & Sullivan recognized PQ Bypass with the 2017 European PAD Interventions Technology Innovation Award for the DETOUR procedure.

The DETOUR™ System is an investigational device and is limited by United States law to investigational use only. It is not available for sale. For more information, please visit www.pqbypass.com.

For further information, please contact Vicky La Touche-Price at Seroba on +3531 63334028.

Recent Articles

Endotronix News

Endotronix Enrolls 1st Patient in SIRONA II CE Mark Trial

LISLE, IL – JULY 15, 2019 – Endotronix, Inc., a digital health and medical technology company dedicated to advancing the […]

Read More
Home V2

Seroba Invests in Storm Therapeutics

20 May 2019.  STORM Therapeutics (“STORM”), the drug discovery company tackling disease through modulating RNA modifying enzymes, has announced that […]

Read More
Quanta SC+

Quanta SC+ confirmed as safe and easy to use

Alcester, Warwickshire, UK, 15 April 2019.  Seroba’s portfolio company, Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a pioneering medical […]

Read More
Fusion

Fusion Raises $105m in Series B Financing

April 2nd 2019. Hamilton, Canada and Dublin, Ireland.  Seroba’s portfolio company, Fusion Pharmaceuticals, a clinical-stage biopharmaceutical company developing targeted alpha-particle […]

Read More
T: 353 (0)1 633 4028

18 Herbert Street
Dublin 2
D02 FK19
Ireland

Scroll to Top